NCT07218913View on ClinicalTrials.gov

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 4, 2026

Primary Completion Date

February 17, 2030

Study Completion Date

February 17, 2030

Conditions
Hearing LossMetastatic Malignant Germ Cell TumorMetastatic Malignant Nongerminomatous Germ Cell TumorMetastatic Malignant Testicular Non-Seminomatous Germ Cell TumorMetastatic Testicular SeminomaStage II Testicular Cancer AJCC v8Stage III Testicular Cancer AJCC v8
Interventions
PROCEDURE

Audiometric Test

Ancillary studies

DRUG

Cisplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Sodium Thiosulfate Anhydrous

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER